Category: Leber Congenital Amaurosis (LCA)

The Difference Between Gene Therapy and Stem Cell Therapy [Facebook Live] (Video)

March 28th, 2018 by FFB Canada

Watch our Facebook Live session, from Friday, March 23, where we were joined online by special guest, Dr. Jill Dolgin from the gene therapy company, AGTC. Dr. Mary Sunderland also talked about the difference between gene therapy and stem cell therapy. News stories that Dr. Sunderland references in the above video: Everything You Need to…

Read More

Stem cell therapy for vision loss: Will it work for you?

March 23rd, 2018 by Dr. Mary Sunderland

In 2015, after a flurry of stem cell developments were profiled in the media, I wrote this story to help answer one of the most popular questions that we receive about stem cell therapies for blindness and sight loss: will they work for you and for your eye disease? On March 19, 2018, the results…

Read More

Top Tech Tips from a Low Vision Specialist [Facebook Live] (Video)

March 6th, 2018 by FFB Canada

On Friday, February 23rd at 12 pm (EST) the Foundation Fighting Blindness visited Dr. Ana Juricic, the Low Vision Doctor, to get her advice on low vision aids and technology. Watch the video below to learn more about exciting advancements and new technologies that could assist people living with vision loss. CLICK HERE to view more…

Read More

Everything You Need to Know About FFB Canada’s Patient Registry

February 6th, 2018 by FFB Canada

Fill out the online form on our Patient Registry page to learn more about how you can enroll. Click here to download a printable version of this article/fact sheet: PDF/Word. The Patient Registry is a secure medical database that was designed to connect people living with inherited retinal diseases (IRDs) to clinical trials, to improve…

Read More

First gene therapy for a blinding eye disease receives FDA approval

December 19th, 2017 by Dr. Mary Sunderland

Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the US that targets a disease caused by mutations in a specific gene. The next steps involve determining the price for Luxturna, which poses…

Read More

Gene Therapy Improves Vision in Landmark Clinical Trial

July 14th, 2017 by Dr. Mary Sunderland

Yesterday, a landmark publication in The Lancet, a prestigious journal, showed that gene therapy can improve vision in people living with a rare blinding eye disease. The study examined the effects of an experimental gene therapy – voretigene neparvovec – to treat an inherited blinding eye disease caused by mutations in the RPE65 gene. RPE65…

Read More